Trialant
Platform
Home
Studies
Other
Contact Us
Terms of Service
Privacy Policy
Toggle Sidebar
Studies
Study
JSON
Overview
Key facts that identify this study and show where it stands today.
Description
What the study is about and why it is being run, in the researchers' own words.
Conditions
The medical conditions and diseases this study investigates.
Interventions
The treatments and procedures being evaluated in this study.
Participation
Who can join this study and the criteria used to decide.
Design
How the study is designed and how its participant groups are organized.
Contacts
The people to reach with questions about this study or how to join it.
Locations
Where the study is run and whether each site is currently recruiting.
Collaborators
The organizations and people involved in this study.
Similar Studies
Other registered studies that closely resemble this one.
Workspace
Home
Studies
Collections
Views
Contact Us
Terms of Service
Privacy Policy
Sign up
NCT05170659
Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab
NCT05170685
No longer available
Expanded Access
Updated Apr 28, 2022
Expanded Access for Abatacept
NCT05170672
No longer available
Expanded Access
Updated May 10, 2022
Expanded Access for Repotrectinib
NCT05926232
Available
Expanded Access
Updated Jul 3, 2023
US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT05627466
No longer available
Expanded Access
Updated Feb 15, 2024
A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies
NCT02061761
Completed
Interventional
Phase 1
Phase 2
Updated Mar 24, 2023
Expanded Access to Risankizumab
NCT03914261
No longer available
Expanded Access
Updated May 24, 2022
Expanded Access for Relatlimab | NCT05170659 | Trialant
Save
Share
No longer available
Expanded Access
Updated Apr 28, 2022
Expanded Access for Relatlimab
ClinicalTrials.gov ID
NCT05170659
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY
Overall Status
No longer available
Study Type
Expanded Access
Last Update Posted
Apr 28, 2022
Actual
Brief Summary
This is an expanded access designed to provide access to Relatlimab for eligible participants.
No conditions
There are no conditions for this study.
Relatlimab
Ages Eligible for Study
Child (0-17)
Adult (18-64)
Older Adult (65+)
Sexes Eligible for Study
No data available
Accepts Healthy Volunteers
No data available
Eligibility Criteria
No data available
No design
There is no design for this study.
No central contacts
There are no central contacts for this study.
No locations
There are no locations for this study.
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY